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Meman tine  and  kynurenic  acid:  curren t  neuroph a r m a c ological  aspect s
Abstrac t:  Glutama t e r gic  neurot r a ns miss ion,  of  special  import anc e  in  the
human  brain,  is  implicated  in  key  brain  functions  such  as  synaptic
plasticity  and  memory.  The  excessive  activation  of  N -methyl- D-aspar t a t e
(NMDA)  recep to r s  may  result  in  excitotoxic  neuronal  damage;  this
process  has  been  implicated  in  the  pathom ec h a ni s m  of  differen t
neurode g e n e r a t ive  disorde r s ,  such  as  Alzheimer’s  disease  (AD).
Meman tine  is  an  uncompe t i t ive  antagonis t  of  NMDA  recep to rs  with  a
favorable  pharm a cokine t ic  profile,  and  is  therefore  clinically  well
tolera t ed .  Memant ine  is  approved  for  the  trea tm e n t  of  AD,  but  may
additionally  be  beneficial  for  other  dementia  forms  and  pain  conditions .
Kynurenic  acid  (KYNA)  is  an  endogenous  antagonis t  of  NMDA  recep to rs
which  has  been  demons t r a t e d  under  experime n t a l  conditions  to  be
neuropro t ec t ive.  The  developm en t  of  a  well- tolera t ed  NMDA  antagonis t
may  offer  a  novel  therape u t ic  option  for  the  trea tm e n t  of
neurode g e n e r a t ive  disease  and  pain  syndrom es .  KYNA may  be  a  valuable
candida t e  for  future  drug  developm en t .  
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List  of  abbrevia t i o n s :
A 1- 42:  amyloid  beta  1-42β
AD: Alzheimer’s  disease
AMPA:  - amino- 3-hydroxy- 5-methyl- 4- isoxazolepropionic  acidα
Ca 2+  : calcium  ion
HD:  Hunting ton’s  disease
IDO:  indoleamine- 2,3- dioxygenas e
KMO:  kynurenine  3-monooxygenas e
KP:  kynurenine  pathway
KYNA: kynurenic  acid
LTP:  long- term  potentia t ion
Mg 2+ : magnesium  ion  
NMDA:  N -methyl- D-aspar t a t e
PD:  Parkinson’s  disease
QUIN:  quinolinic  acid
Introd u c t i o n
Glutama t e  is  the  main  excita tory  neurot r a ns mi t t e r  in  the  human  brain,
and  glutam a t e- media ted  neurot r an s miss ion  is  of  high  impor tance  in
several  key  brain  functions  such  as  synaptic  plas ticity  and  memory
formation.  NMDA  recep to r s  are  widely  distributed  in  the  human  brain
and  they  are  of  special  impor tanc e  in  both  excita tory  neurot r a ns mis sion
and  neurodeg e n e r a t ive  processe s .  Under  physiological  resting  poten tials ,
more  than  90%  of  the  NMDA  recepto rs  are  blocked  by  magnesium  ions
(Mg 2+ ).  Postsynap t ic  depola riza tion  of  the  membra n e s  resul ts  in  the
release  of  Mg 2+  and  allows  NMDA  activation.  The  voltage- depende n t  Mg 2+
block  is  able  to  influence  excita tory  postsynap t ic  poten tials ,  and  underlies
the  differen t  responses  of  the  various  subtypes  of  NMDA  recepto rs .  The
NR2  subunit  of  the  NMDA  recep to r s  dete rmines  the  voltage  depende nc e:
the  NR2A-  and  NR2B- containing  subtypes  are  blocked  more  strongly  than
the  NR2C  or  NR2D- containing  subtypes 1 .  The  NMDA  recep to rs  are
member s  of  the  ionotropic  recepto r  family,  and  possess  high  calcium
(Ca 2+ )  permea bili ty.  The  NMDA  recepto rs  also  play  an  importa n t  role  in
the  induction  of  long- term  potentia t ion  (LTP),  e.g.  a  long- lasting  increas e
of  the  synaptic  streng th  or  long- term  depress ion,  e.g.  a  decreas e  of  it.
LTP  and  long- term  depression  are  the  basis  of  synaptic  plasticity,  and  are
considere d  to  be  key  process es  in  memory  and  learning 2 . 
Overact ivat ion  of  the  NMDA  recep to rs  results  in  excessive  Ca 2+  influx
into  the  cells,  activating  various  signaling  pathways  which  may  lead  to
neuronal  damage;  this  process  is  known  as  excitotoxicity 3 .  Excitotoxicity
has  been  implica ted  in  a  number  of  pathological  processe s  such  as
cereb ra l  ischemia  and  neurodeg e n e r a t ive  diseases 4 ,  5 .  Earlier  attempt s  to
use  NMDA  antagonis t s  as  therape u t ic  agents  failed  despite  the  promising
preclinical  resul ts ,  because  they  were  either  ineffective  in  the  clinical
set ting  or  resul ted  in  unaccep t a ble  side- effects ,  such  as  a  cognitive
impairm en t 6-8 . However ,  these  resul ts  promoted  a  bet te r  unders t a n ding  of
the  role  of  the  glutama t e r gic  neurot r a n s miss ion  in  physiological  brain
functions  such  as  cognitive  process es  and  memory.  On  the  other  hand,  in
pathological  cases,  where  the  excita tory  recep to rs  are  overact ivat ed ,  the
inhibition  of  NMDA  recepto rs  may  be  beneficial  by  reest ablishing  the
physiological  glutam a t e r gic  balance ,  and  preventing  excitotoxic  neuronal
damage  without  attenu a t ing  the  normal  neurot r a n s mission 9. 
Meman tine  was  the  first  NMDA  antagonis t  approved  for  the  therapy  of
modera t e  to  severe  Alzheimer’s  disease  (AD) 10 ,  11 .  Curren tly  no  other
NMDA  antagonis t  agents  are  available  in  clinical  practice,  and  it  is  still  a
challenge  to  develop  effective  neuropro tec t ive  drugs  capable  of
preventing  the  pathological  activation  of  NMDA  recepto rs  without
impairing  their  physiological  activity.  
The  kynurenine  pathway  (KP)  of  the  tryptopha n  metabolism  leads  to  the
formation  of  several  neuroac t ive  molecules ,  including  the  NMDA-
antagonis t  kynurenic  acid  (KYNA),  which  has  shown  promise  as  a
neuropro t ec t ive  agent  in  the  preclinical  setting.  This  review  will  focus  on
the  neuropha r m a c ological  proper t i es  of  the  NMDA- antagonis t  meman t ine
and  KYNA,  with  special  focus  on  AD,  describing  the  similari ties  and
future  potential  for  drug  developme n t .
Mem a n t i n e  
Meman tine  (1-amino- 3,5- dimethylada m a n t a n e ;  Figur e  1. )  was  first
synthe t ized  in  1968,  but  its  NMDA- antagonis t ic  proper ty  was  discovere d
only  in  the  1980s 12 ,  13 .  It  is  an  uncompe ti t ive  open- channel  blocker  which
exer ts  its  effect  by  inhibiting  Ca 2+  influx  at  excessive  NMDA  activation,
while  it  does  not  interfer e  with  physiological  activation  ( Figure  2. )14 .  In
rats,  the  adminis t ra t ion  of  5-10  mg/kg  memant ine  resul ted  in  a  plasma
level  of  1.0- 3.2  mM,  while  the  brain  levels  achieved  after  the  i.p.  injection
of  10  or  20mg/kg  meman t ine  were  1.2  and  2.6  mM,  respec t ively 15 .  The
IC 50  of  me m a n t i n e  is  approxi m a t e ly  3  µM,  which  is  in  good
accorda nce  with  its  therape u t ic  concen t r a t ion  range  in  humans  16 ,  17 .  In
AD  patient s ,  the  recom me n d e d  therap e u t ic  dose  is  20  mg/day 11 .  The
adminis t ra t ion  of  5-30  mg/day  of  meman tine  to  humans  results  in
cereb rospinal  fluid  concen t r a t ions  of  0.05- 0.31  M  and  serumμ
concen t r a t ions  of  0.025  to  0.529  Mμ 17 , 18 . The  elimina tion  half- life  of  orally
adminis te r e d  memant ine  in  the  human  serum  is  60–80  h 19 . 
The  experimen t a l  data  indicate  that  meman t ine  binds  to  the  same
channel  site  as  Mg 2+ ,  and  it  does  not  interfe re  with  the  glutama t e  or
glycine  binding  site 15 .  The  assumption  that  it  shares  their  binding  site
with  Mg 2+  is  suppor t ed  by  the  observa t ion  that  Mg 2+  decreas e s  the
NMDA- antagonis tic  effect  of  memant ine ,  and  that  muta tions  in  the  NR1
and  NR2  subuni ts  which  are  importan t  for  Mg 2+  binding  also  influence
meman t ine  block 17 ,  20 ,  21 .  Chen  et  al.  described  a  slow  unblocking  phase  of
this  substanc e  from  the  NMDA  recepto rs ,  which  was  inhibited  by  the
presence  of  Mg 2+  22 .  Meman tine  has  no  effect  on  the  curren t s  evoked  by
kainate  or  quisquala t e  either 22 .  High  concen t r a t ions  of  this  compound
have  been  sugges t e d  to  poten tia t e  a-amino- 3-hydroxy- 5-methyl- 4-
isoxazolepropionic  acid  (AMPA)- induced  curren t s  in  neuronal  culture s ,
but  this  effect  was  modera t e  and  therefore  its  relevance  is  unclear 15 .
Meman tine  displays  low  affinity  for  the  NMDA  recep to r s ;  the  binding  is
strongly  voltage- depende n t ,  with  fast  double  exponen t ial  blocking
kinetics,  which  is  strongly  depende n t  on  the  agonis t  concen t r a t ion 23 ,  24 .
Besides  NMDA  antagonism,  meman tine  has  been  demons t r a t e d  to
influence  glutama t e  levels.  The  chronic  administ r a t ion  of  meman t ine
resulted  in  a  decreas e d  hippoca mp al  glutama t e  level,  and  decreas e d
glutama t e r g ic  neurot r a n s mission  in  the  frontal  cortex 25 ,  26 .  The
neuropro t ec t ive  effect  of  memant ine  has  been  confirmed  by  several
studies,  indicating  that  it  prevents  the  toxic  effects  of  NMDA  and  NMDA-
recepto r  agonis ts  in  cultured  cortical  neurons,  cultured  retinal  ganglion
cells  or  the  chick  retina  in  vitro 22 , 27- 29 . 
An  intriguing  aspec t  of  the  glutama t e  antagonis t  meman t ine  is  its  ability
to  improve  cognitive  functions.  The  possible  explana tions  of  this  paradox
effect  include  a  decreas e  of  synaptic  “noise”  induced  by  NMDA  recep to r
overact ivat ion  and  restor a t ion  of  the  physiological  glutam a t e r g ic
balance 15 ,  17 .  Although  NMDA  recepto r s  are  necessa ry  for  some  forms  of
LTP,  the  basis  of  the  learning  process,  overac tiva tion  may  result  in
impairm en t .  In  these  cases ,  memant ine  may  actually  improve  synaptic
plasticity  and  cognition.  Experime n t a l  data  have  indicated  that  it  is  able
to  prolong  the  dura tion  of  LTP  in  rats 30 .  Depletion  of  Mg 2+  resul ts  in  the
impairm en t  of  LTP  in  hippocam p al  slices,  an  effect  attenua t e d  by
meman t ine 31 .  In  accordanc e  with  this,  memant ine  also  reverse s  the
reduc tion  of  LTP  in  the  CA1  region  of  the  hippocam p us  induced  by
NMDA 32 .  Accordingly,  this  drug  significantly  improves  cognitive  functions
in  modera t e  to  severe  AD  patien t s  and  it  has  been  approved  for  this
indication  in  both  the  Europea n  Union  and  the  USA 19 ,  33 .  This  effect  may
be  partly  media ted  by  its  influence  on  glutama t e r gic  neurot r a ns miss ion,
but  it  may  be  related  in  par t  to  the  counte r ac t ion  of  amyloid  toxicity.  In
cultured  primary  cortical  neurons  from  rats  memant ine  was  able  to
attenua t e  the  tau-  phosphoryla tion  induced  by  A 1-42β 34 .  In  anoth e r
study,  me m a n t i n e  was  able  to  preve n t  cogn i t ive  decl in e  in  triple-
trans g e n i c  (3xTg- AD)  mice ,  and  the  treat m e n t  also  resul t e d  in  a
signi f ic a n t  reduct i o n  in  the  level s  of  insolu b l e  amyloid  beta,  total
tau  and  hyperp h o s p h o ry la t e d  tau 35 .
This  pharma con  might  also  offer  a  therap e u t ic  option  in  other
neurode g e n e r a t ive  disorde r s ,  such  as  Parkinson’s  disease  (PD)  or
Hunting ton’s  disease  (HD).  In  a  small  study,  meman t ine  slowed  the
progre ss ion  of  the  neurode ge n e r a t ive  process  in  HD 36 .  It  also  improves
PD  dement ia  and  surprisingly  displays  beneficial  symptom a t ic  effects  on
the  motor  symptoms  too 37- 40 . Case  repor t s  have  sugges t ed  that  memant ine
may  also  improve  levodopa- induced  dyskinesia ,  but  furthe r  studies  are
merited  to  confirm  this 41 ,  42 .  Another  field  of  neurology  where  this  drug
may  be  beneficial  is  migraine .  Some  smaller  studies  have  sugges t e d  that
it  may  be  able  to  reduce  the  frequency  of  headach e 43 ,  44 .  Furthe r  large-
scale  studies  are  awaited  to  confirm  this  observa t ion.  Neuropa t h ic  pain
syndromes  affect  a  broad  range  of  the  populat ion,  but  their  therap e u t ic
manage m e n t  has  not  yet  been  fully  resolved.  Meman tine  effectively
alleviated  the  developme n t  of  neuropa t hic  pain  in  rats  and  also  achieved
significant  antinocicep tion  in  an  animal  model  of  diabe tic  neuropa t h ic
pain 45 ,  46 .  A clinical  trial  is  ongoing  to  investigat e  its  efficacy  to  prevent
post- mastec tomy  neuropa t hic  pain  in  breas t  cancer  patien t s 47 .  The  fact
that  me m a n t i n e  is  clinica l ly  well  tolerat e d  can  be  attribut ab l e  to
its  favorabl e  pharm a c o k i n e t i c  proper t i e s 17 , 48 .
Kynure n i c  acid  
KYNA  is  one  of  the  neuroac t ive  metaboli tes  synthesized  in  the  KP  of
tryptopha n  metabolism  (Figur e  3.) .  The  KP  produces  not  only  the
neuropro t ec t ive  KYNA,  but  also  several  neurotoxic  metabolites ,  such  as
quinolinic  acid  (QUIN)  and  3-hydroxykynure nine .  QUIN,  an  endo g e n o u s
agoni s t  of  NMDA  recepto r s ,  additionally  induces  endogenous  antioxidan t
depletion,  contribu te s  to  free  radical  genera t ion  and  induces  lipid
peroxidation 49- 51 .  Moreover ,  QUIN  has  been  confirmed  to  increase
presynap t ic  glutam a t e  release  and  reduce  glutama t e  uptake  by  the
ast rocyte s 52 ,  53 .  On  the  other  hand,  KYNA  is  the  only  know n  broad-
spec tr u m  endo g e n o u s  inhibi tor  affec t i n g  all  ionotro pi c  gluta m a t e
rece pt or s .  It  is  able  to  block  NMDA,  AMPA  and  kainat e  subtypes ,  but
has  a  highes t  affinity  for  NMDA  recep to r s  which  are  the  most  perme a ble
recepto r s  for  Ca2 + 7 ,  54 ,  55 .  NMDA  recep t or s  are  tetra m e r  struct u r e s
which  cons i s t  of  four  subu n i t s .  The  most  preval e n t  forms  in  the
brain  conta in  NR1  and  NR2  subu n i t s .  The  NR1  subu n i t  conta i n s
the  glycin e - bindin g  site ,  where a s  the  NR2  subu n i t  conta i n s  the
gluta m a t e - bindin g  site .   At  low  micro m o l ar  con c e n tr a t i o n s  (EC 50
=7. 9  to  15  µM),  KYNA  binds  with  high  affini ty  to  the  strych n i n e -
inse n s i t iv e  glycin e - bindin g  site  on  the  NR1  subu n i t  of  the  NMDA
rece pt or s ,  where a s  at  10- 20  time s  high er  conc e n tr a t i o n s  (EC50 =
200  to  500  µM)  it  is  able  to  block  the  gluta m a t e - bindin g  site  on
the  NR2  subu ni t  as  well 56 ,  57 .  The  neuropro t ec t ive  effect  of  KYNA  is
mainly  attribu ted  to  the  preven tion  of  glutama t e  excitotoxicity  via
antagonism  of  the  NMDA  recep to rs .  KYNA  displays  antagonis t ic
proper t ies  at  the  presynap tic  7  nicotinic  acetylcholine  recepto rs ,α
inhibiting  them  in  a  noncompe t i t ive  manne r ,  which  is  involved  in  the
presynap t ic  regula tion  of  glutam a t e  release 58 ,59 .  Low  KYNA
concen t r a t ions  inhibit  presynap t ic  glutam a t e  release ,  thereby
contributing  to  its  neurop ro tec t ive  effect 60 .  Interes t ingly,  KYNA  exert s  a
dose- depende n t  dual  effect  on  the  AMPA  recep to r s :  in  the  micromolar
concen t r a t ion  range,  KYNA  inhibits  them,  where as  in  low  nanomola r
concen t r a t ions  it  evokes  facilita tion 61 ,62 .  The  facilita tory  effect  is  probably
associa ted  with  a  positive  modula to ry  binding  site  at  the  AMPA  recepto r s .
A  recent  work  provided  data  relating  to  the  possible  molecula r
mechanism s,  but  furthe r  investiga t ions  are  definitely  warran t e d 63 .  KYNA
has  been  identified  as  a  ligand  for  the  previously  orphan  G-protein-
coupled  recep to r  too 64 .  The  complex  molecula r  interac t ions  of  KYNA with
the  differen t  recep to r s  underlie  its  impor tance  in  the  physiological
processe s  of  the  central  nervous  system,  and  sugges t  its  neuromodula to ry
and  regula to ry  functions.  
Altera t ions  in  the  delicate  balance  of  the  neurotoxic  and  neuropro t ec t ive
compounds  of  the  KP  have  been  implicated  in  the  pathomec h a ni s m s  of
several  neurodege n e r a t ive  diseases ,  such  as  AD  or  PD,  and  stroke 65 ,  66 .
The  activity  of  indoleamine- 2,3- dioxygenas e  (IDO),  which  is  responsible
for  the  rate- limiting  step  of  the  KP,  has  been  demons t r a t e d  to  be
increas ed  in  AD  and  stroke,  reflecting  an  increase d  activation  of  the
metabolic  cascade  66 ,  67 .  The  IDO  activity  has  been  confirmed  to  be
increas ed  in  the  hippocam p us  of  AD patien ts ,  togethe r  with  an  elevated
immunore a c t ivity  of  the  neurotoxic  QUIN 68 .  In  human  macropha g e s  and
microglia,  A 1-42  induces  IDO  expression  and  QUIN  produc tionβ 69 .  QUIN
has  been  described  to  be  co- localized  with  hyperphosp ho ryla t ed  tau  in
the  cortex  of  AD  patient s ,  and  it  also  resul ts  in  tau  phospho ryla tion  in
primary  neuron  cultures 70 .  Altera t ions  in  the  KP  have  likewise  been
described  in  PD,  HD  and  stroke  (reviews  in 71 , 72 ).  
Elevated  KYNA  levels  have  proved  to  be  neurop ro tec t ive  under  differen t
experimen t a l  conditions  of  neurotoxici ty.  The  promising  resul ts  in
experimen t a l  studies  can  mainly  be  explained  by  the  prevention  of
glutama t e  excitotoxicity,  but  other  possible  mechanis ms  have  also  been
sugges t ed .  In  an  in  vitro  study,  KYNA  induced  the  gene  express ion  and
activity  of  neprilysin,  an  enzyme  participat ing  in  the  metabolism  of  A ,β
and  this  resul ted  in  increase d  neuronal  cell  survival 73 . These  data  indicate
that  the  neuropro t ec t ive  effect  of  KYNA may  be  related,  at  least  in  par t ,
to  the  induction  of  amyloid  degrad a t ion .  Furthe r ,  KYNA  has  been
confirmed  to  exert  beneficial  effects  in  PD  and  pain  syndromes .  In  an
experimen t a l  animal  model  of  PD,  KYNA  effectively  alleviated
parkinsonian  motor  symptoms 74 . 
Elevation  of  the  KYNA  level  in  the  brain  is  challenging,  because  KYNA
itself  can  cross  the  blood- brain  barrie r  only  poorly;  however ,  there  are
various  methods  to  achieve  this.  
 The  first  option  is  the  administ r a t ion  of  kynurenine ,  which  is  the  prodrug
of  KYNA,  togethe r  with  probenecid,  an  organic  aminoacid  transpor t e r
inhibitor;  this  was  able  to  preven t  the  neuronal  damage  induced  by
soluble  A  and  also  significantly  improved  spatial  memoryβ 75 .  This
trea tm e n t  was  also  neurop ro tec t ive  in  the  6-hydroxydopa mine  animal
model  of  PD 76 . The  same  trea tm e n t  regime  exerted  beneficial  effects  in  an
animal  model  of  neuropa t h ic  pain  by  diminishing  the  allodynia 77 .  Another
possible  option  is  the  use  of  kynurenine- 3-monooxygenas e  (KMO)
inhibitors ,  which  resul ts  in  a  shift  of  the  KP  toward  produc tion  of  the
neuropro t ec t ive  KYNA.  A  synthe t ic  KMO  inhibitor  has  been  described
that  exer ts  beneficial  effects  in  an  animal  model  of  AD  by  preven ting
neuronal  damage  and  also  spatial  memory  deficits 78 .  KMO  inhibition  has
additionally  been  described  to  improve  levodopa- induced  dyskinesia
without  diminishing  the  antiparkinsonian  effect  of  simultaneously
adminis te r e d  levodopa 79 , 80 . 
Synthe t ic  kynurenine  derivatives  may  repres e n t  anothe r  therape u t ic
option;  these  molecules  have  proved  neuropro t ec t ive  in  the  1-methyl- 4-
phenyl- 1,2,3,6- tetrahydropyridine  model  of  PD 81 .  A  halogena t e d  KYNA
derivative,  4-chlorokynure nine ,  has  also  been  confirmed  to  prevent
cellular  damage  in  a  toxic  animal  model  of  AD 82 . A novel  KYNA amide  was
neuropro t ec t ive  in  experime n t a l  models  of  HD 83 .  The  same  analog
demons t r a t e d  a  significan t  neuropro t ec t ive  capaci ty  and  prevente d
neuronal  damage  in  hippocam p al  CA1  pyramids  in  an  experimen t a l  model
of  global  cerebra l  forebrain  ischemia  in  rats 84 .  An  in  vitro  compara t ive
elect rophysiological  study  confirmed  that  this  analog  displays  the  same
neuromodula to ry  proper t ie s  as  KYNA 85 .  In  an  experime n t a l  migraine
model,  this  compound  reduced  c-fos  and  nNOS  86 , 87 . 
An  import an t  aspect  of  NMDA  antagonis t  therapies  is  the  possibility  of
cognitive  side- effects.  The  novel  KYNA  analog  2- (2- N,N -
dimethylaminoe thyla mine- 1-carbonyl)- 1H- quinolin- 4-one  hydrochloride
has  therefore  been  investiga t ed  in  differen t  behavioral  paradigms  to
assess  its  side- effect  profile.  The  results  confirmed  that  in  a  dose  in  which
it  exerted  its  neurop ro t ec t ive  effect,  this  KYNA  derivative  did  not  give
rise  to  any  significant  systemic  side- effect 88 .  Other  studies  also  showed
that  elevation  of  KYNA  levels  in  the  brain  did  not  resul t  in  further
worsening  of  working  memory  function 89 .  Its  effects  have  been
investiga t e d  on  locomotor  activity,  working  memory  performa nc e  and
long- lasting,  consolidat ed  reference  memory  by  the  means  of  open  field,
radial  arm  maze  and  Morris  wate r  maze  paradigms.  In  these  experime n t s ,
it  did  not  impair  the  cognitive  functions  of  the  brain 90 .  Furthe r m o r e ,  an
elect rophysiological  study  of  the  effects  of  this  analog  on  the  cognitive
functions  revealed  that  did  not  decreas e  LTP  as  might  have  been
expected  from  its  NMDA  antagonis t ic  proper t i es ,  but  rather  facilita ted
the  potentia t ion  of  field  excita tory  postsynap tic  potentials 91 .  The
explana t ion  of  this  somewha t  paradoxical  effect  may  be  the  observa t ion
that  the  elevation  of  KYNA levels  resul ts  in  a  prefere n t ial  inhibition  of  the
extrasynap t ic  NMDA  recep to r s  and  presynap t ic  nicotinic  acetylcholine
recepto r s ,  wherea s  the  synaptic  NMDA  and  AMPA  recep to r- mediat ed
curren t s  are  relatively  spared  (reviewed  in 92 ).  The  slight  facilita tory  effect
of  the  KYNA analog  may  possibly  be  related  to  the  Janus- faced  natu re  of
KYNA,  e.g.  its  concen t r a t ion- depende n t  dual  effect  on  AMPA  recep to rs
(Figur e  4. ).  
The  NMDA  recep t or s  play  critica l  role s  in  normal  brain  funct io n
(me m o ry ,  synapt i c  com m u n i c a t i o n  and  control l i n g  synapt i c
plast i c i ty ) .  Consi s t e n t ly ,  their  antag o n i s t s  applie d  as  poten t i a l
therap e u t i c  drug s  frequ e n t ly  failed  due  to  seriou s  side- effec t s 7 ,  93 .
The  main  parall e l i ty  betwe e n  me m a n t i n e  and  KYNA  is  repre s e n t e d
by  their  effec t s  on  NMDA  rece pt or s ,  both  havin g  been
hypoth e s i z e d  to  allow  their  normal  physio l o g i c a l  activat io n  while
inhibi t i n g  their  patho l o g i c a l  exci to t ox i c  overact ivat i o n 17 ,  94 .
How ev er,  their  mec h a n i s m  of  act ion  is  differe n t .  Mema n t i n e  is  a
trappin g  open- chan n e l  block er  of  thes e  recep t or s ,  where a s  KYNA
binds  as  an  inhibi tor  at  both  the  strych n i n e - ins en s i t iv e  glycin e -
bindin g  site  at  low  conc e n tr a t i o n s ,  and  at  the  NMDA  reco g n i t i o n
site  at  high  conc e n tr a t i o n s ,  bein g  a  broad- spec tr u m ,  non- sel ec t iv e
gluta m a t e  recep t or  anta g o n i s t 95 .  Their  overlappi n g  therap e u t i c
pote n t i a l  furth er  refle c t s  their  similar  proper t i e s  and  effec t s .
Mem a n t i n e  is  an  importa n t  player  in  the  therapy  of  mod er a t e - to-
sever e  AD;  howev er ,  its  bene f i c i a l  effec t  has  also  bee n  sug g e s t e d
in  PD,  HD,  neurop a t h i c  pain,  epil ep sy ,  and  mult ip l e  sclero s i s  as
well 11 ,  15 ,  46 ,  48 ,  96- 100 .  the  neuropro t e c t iv e  propert i e s  of  KYNA  might  be
also  be  bene f i c ia l  in  treat m e n t  of  AD,  PD,  MS,  neurop at h i c  pain  as
well  75 , 101- 103 .
Moreover  the  beneficial  effect  of  the  NMDA  antagonis t  memant ine  and
KYNA  on  cognitive  functions  exhibit  marked  similarities.  Interes t ingly,
meman t ine  has  recen tly  been  demons t r a t e d  to  enhanc e  the  produc tion  of
KYNA,  which  may  lead  in  par t  to  the  beneficial  therape u t ic  effect  of  this
compound 104 .  KYNA may  contribu te  to  the  NMDA- antagonis tic  proper t i es
of  meman t ine ,  and  both  compounds  are  also  able  to  influence
acetylcholine  recep to rs 104 . These  cholinergic  recep to r s  have  recen tly  been
sugges t ed  to  contribu te  to  AD  pathology  by  promoting  amyloid
accumula t ion  in  the  neurons 105 .  Furthe r  investiga tions  are  merited  to
assess  the  poten tial  interac t ions  of  meman tine  and  KYNA.  On  the  other
hand,  KYNA  and  its  analog  may  serve  as  promising  candida t e s  for  the
future  developme n t  of  well- tolera t ed  partial  NMDA  antagonis t s .
Impor tan t ly,  a  recent  study  demonst r a t e d  that  orally  adminis te r e d  KYNA
did  not  decreas e  cell  viability  in  differen t  cell  culture s ,  nor  affect  body
gain  or  blood  counts  in  roden ts .  The  study  confirmed  that  KYNA is  well-
tolera t ed  in  rats  and  mice  and  does  not  display  any  toxic  effect.  These
findings  sugges t  that  oral  KYNA  adminis t ra t ion  would  not  be  toxic  in
humans  either  106 .  An  importa n t  aspe c t  for  future  drug  develop m e n t
is  the  fact,  that  KYNA  is  an  endo g e n o u s  comp o u n d ;  howev er,
synth e t i c  KYNA  analo g s  or  nanot e c h n o l o g y - based  approa c h e s  may
hold  promi s e  for  drug  develo p m e n t  with  the  aim  to  achi ev e  bett er
pharm a c o l o g i c a l  prop er t i e s .  
Conclu s i o n s
As  an  open- channel  blocker  NMDA  antagonis t  meman tine  is  clinically
well  tolera t ed  and  effective  for  the  trea tm e n t  of  AD  and  other  forms  of
cognitive  impairme n t .  Its  poten tial  therape u t ic  benefits  have  been
sugges t ed  in  other  conditions  too,  such  as  migraine  or  neuropa t h ic  pain.
KYNA  and  its  synthe t ic  derivatives  display  several  similari ties  to
meman t ine  as  concerns  their  mode  of  action,  e.g.  par tial  NMDA  recep to r
inhibition  and   7  nicotinic  acetylcholine  recepto r  inhibition.  A  novelα
KYNA  analog  has  proved  neurop ro tec t ive  in  differen t  experimen t a l
set tings,  and  does  not  induce  any  significant  systemic  side- effect;  indeed,
it  improves  the  LTP.  Furthe r  investigat ions  are  called  for  to  assess  the
poten tial  therape u t ic  value  of  KYNA  derivatives  with  the  aim  of
neuropro t ec t ion  and  cognitive  improveme n t .  
Conflic t  of  intere s t
The  authors  declare  that  they  have  no  conflict  of  interes t  and  have  
received  no  payment  in  the  prepa r a t ion  of  their  manusc rip t .
Acknowl e d g m e n t s
This  work  was  suppor t ed  by  the  project  TÁMOP- 4.2.2.A- 11/1/KONV- 2012-
0052,  by  the  Hunga r ian  Brain  Research  Progra m  (NAP,  Grant  No.  
KTIA_13_NAP- A-III/9.  and  KTIA_13_NAP- A-II/17.),  by  EUROHEADPAIN  
(FP7- Health  2013- Innovation;  Grant  No.  602633),  by  OTKA K105077  and  
by  the  MTA-SZTE  Neuroscienc e  Resea rc h  Group  of  the  Hunga ri an  
Academy  of  Sciences  and  the  Universi ty  of  Szeged.
Refere n c e s  
1. Kuner, T.; Schoepfer, R. Multiple structural elements determine subunit specificity of Mg2+ 
block in NMDA receptor channels. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 1996, 16 (11), 3549-58.
2. Cooke, S. F.; Bliss, T. V. Plasticity in the human central nervous system. Brain, 2006, 129 (Pt 
7), 1659-73.
3. Sattler, R.; Tymianski, M. Molecular mechanisms of glutamate receptor-mediated excitotoxic 
neuronal cell death. Mol Neurobiol, 2001, 24 (1-3), 107-29.
4. Zadori, D.; Klivenyi, P.; Szalardy, L.; Fulop, F.; Toldi, J.; Vecsei, L. Mitochondrial disturbances, 
excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for 
neurodegenerative disorders. J Neurol Sci, 2012, 322 (1-2), 187-91.
5. Mehta, A.; Prabhakar, M.; Kumar, P.; Deshmukh, R.; Sharma, P. L. Excitotoxicity: bridge to 
various triggers in neurodegenerative disorders. European journal of pharmacology, 2013, 698 (1-3), 
6-18.
6. Palmer, G. C. Neuroprotection by NMDA receptor antagonists in a variety of 
neuropathologies. Curr Drug Targets, 2001, 2 (3), 241-71.
7. Lipton, S. A. Failures and successes of NMDA receptor antagonists: molecular basis for the 
use of open-channel blockers like memantine in the treatment of acute and chronic neurologic 
insults. NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2004, 1 
(1), 101-10.
8. Chen, L.; Yamada, K.; Nabeshima, T.; Sokabe, M. alpha7 Nicotinic acetylcholine receptor as a 
target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. 
Neuropharmacology, 2006, 50 (2), 254-68.
9. Parsons, C. G.; Stoffler, A.; Danysz, W. Memantine: a NMDA receptor antagonist that 
improves memory by restoration of homeostasis in the glutamatergic system--too little activation is 
bad, too much is even worse. Neuropharmacology, 2007, 53 (6), 699-723.
10. Lipton, S. A.; Chen, H. S. Paradigm shift in neuroprotective drug development: clinically 
tolerated NMDA receptor inhibition by memantine. Cell death and differentiation, 2004, 11 (1), 18-
20.
11. Witt, A.; Macdonald, N.; Kirkpatrick, P. Memantine hydrochloride. Nature reviews. Drug 
discovery, 2004, 3 (2), 109-10.
12. Bormann, J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor 
channels. European journal of pharmacology, 1989, 166 (3), 591-2.
13. Kornhuber, J.; Bormann, J.; Retz, W.; Hubers, M.; Riederer, P. Memantine displaces [3H]MK-
801 at therapeutic concentrations in postmortem human frontal cortex. European journal of 
pharmacology, 1989, 166 (3), 589-90.
14. Danysz, W.; Parsons, C. G.; Mobius, H. J.; Stoffler, A.; Quack, G. Neuroprotective and 
symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic 
hypothesis on the mechanism of action. Neurotox Res, 2000, 2 (2-3), 85-97.
15. Parsons, C. G.; Danysz, W.; Quack, G. Memantine is a clinically well tolerated N-methyl-D-
aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology, 1999, 38 
(6), 735-67.
16. Parsons, C. G.; Gruner, R.; Rozental, J.; Millar, J.; Lodge, D. Patch clamp studies on the kinetics
and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-
dimethyladamantan). Neuropharmacology, 1993, 32 (12), 1337-50.
17. Johnson, J. W.; Kotermanski, S. E. Mechanism of action of memantine. Current opinion in 
pharmacology, 2006, 6 (1), 61-7.
18. Kornhuber, J.; Quack, G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-
aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett, 1995, 195 (2), 137-9.
19. Sonkusare, S. K.; Kaul, C. L.; Ramarao, P. Dementia of Alzheimer's disease and other 
neurodegenerative disorders--memantine, a new hope. Pharmacological research, 2005, 51 (1), 1-17.
20. Sobolevsky, A. I.; Koshelev, S. G.; Khodorov, B. I. Interaction of memantine and amantadine 
with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J 
Physiol, 1998, 512 ( Pt 1), 47-60.
21. Kashiwagi, K.; Masuko, T.; Nguyen, C. D.; Kuno, T.; Tanaka, I.; Igarashi, K.; Williams, K. 
Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the 
vestibule and ion channel pore. Mol Pharmacol, 2002, 61 (3), 533-45.
22. Chen, H. S.; Pellegrini, J. W.; Aggarwal, S. K.; Lei, S. Z.; Warach, S.; Jensen, F. E.; Lipton, S. A. 
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic 
advantage against NMDA receptor-mediated neurotoxicity. The Journal of neuroscience : the official 
journal of the Society for Neuroscience, 1992, 12 (11), 4427-36.
23. Gilling, K. E.; Jatzke, C.; Parsons, C. G. Agonist concentration dependency of blocking kinetics 
but not equilibrium block of N-methyl-D-aspartate receptors by memantine. Neuropharmacology, 
2007, 53 (3), 415-20.
24. Gilling, K. E.; Jatzke, C.; Hechenberger, M.; Parsons, C. G. Potency, voltage-dependency, 
agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-
methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) 
receptors. Neuropharmacology, 2009, 56 (5), 866-75.
25. Glodzik, L.; King, K. G.; Gonen, O.; Liu, S.; De Santi, S.; de Leon, M. J. Memantine decreases 
hippocampal glutamate levels: a magnetic resonance spectroscopy study. Prog 
Neuropsychopharmacol Biol Psychiatry, 2008, 32 (4), 1005-12.
26. van Wageningen, H.; Jorgensen, H. A.; Specht, K.; Hugdahl, K. A 1H-MR spectroscopy study of 
changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of 
memantine. Cerebral cortex, 2010, 20 (4), 798-803.
27. Erdo, S. L.; Schafer, M. Memantine is highly potent in protecting cortical cultures against 
excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. European journal of 
pharmacology, 1991, 198 (2-3), 215-7.
28. Osborne, N. N.; Quack, G. Memantine stimulates inositol phosphates production in neurones 
and nullifies N-methyl-D-aspartate-induced destruction of retinal neurones. Neurochem Int, 1992, 21 
(3), 329-36.
29. Weller, M.; Finiels-Marlier, F.; Paul, S. M. NMDA receptor-mediated glutamate toxicity of 
cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine 
and memantine. Brain Res, 1993, 613 (1), 143-8.
30. Barnes, C. A.; Danysz, W.; Parsons, C. G. Effects of the uncompetitive NMDA receptor 
antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation 
and spatial memory in awake, freely moving rats. The European journal of neuroscience, 1996, 8 (3), 
565-71.
31. Frankiewicz, T.; Parsons, C. G. Memantine restores long term potentiation impaired by tonic 
N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal 
slices. Neuropharmacology, 1999, 38 (9), 1253-9.
32. Zajaczkowski, W.; Frankiewicz, T.; Parsons, C. G.; Danysz, W. Uncompetitive NMDA receptor 
antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. 
Neuropharmacology, 1997, 36 (7), 961-71.
33. Schmitt, F.; Ryan, M.; Cooper, G. A brief review of the pharmacologic and therapeutic aspects
of memantine in Alzheimer's disease. Expert Opin Drug Metab Toxicol, 2007, 3 (1), 135-41.
34. Song, M. S.; Rauw, G.; Baker, G. B.; Kar, S. Memantine protects rat cortical cultured neurons 
against beta-amyloid-induced toxicity by attenuating tau phosphorylation. The European journal of 
neuroscience, 2008, 28 (10), 1989-2002.
35. Martinez-Coria, H.; Green, K. N.; Billings, L. M.; Kitazawa, M.; Albrecht, M.; Rammes, G.; 
Parsons, C. G.; Gupta, S.; Banerjee, P.; LaFerla, F. M. Memantine improves cognition and reduces 
Alzheimer's-like neuropathology in transgenic mice. The American journal of pathology, 2010, 176 
(2), 870-80.
36. Beister, A.; Kraus, P.; Kuhn, W.; Dose, M.; Weindl, A.; Gerlach, M. The N-methyl-D-aspartate 
antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl, 2004,  
(68), 117-22.
37. Aarsland, D.; Ballard, C.; Walker, Z.; Bostrom, F.; Alves, G.; Kossakowski, K.; Leroi, I.; Pozo-
Rodriguez, F.; Minthon, L.; Londos, E. Memantine in patients with Parkinson's disease dementia or 
dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol, 
2009, 8 (7), 613-8.
38. Li, W.; Zhao, J. H.; Sun, S. G.; Zhang, J. W.; Suo, A. Q.; Ma, M. M. [Clinical rehabilitative effect 
of memantine on cognitive and motor disorders in patients with Parkinson's disease]. Zhonghua Yi 
Xue Za Zhi, 2011, 91 (5), 301-3.
39. Leroi, I.; Overshott, R.; Byrne, E. J.; Daniel, E.; Burns, A. Randomized controlled trial of 
memantine in dementia associated with Parkinson's disease. Mov Disord, 2009, 24 (8), 1217-21.
40. Moreau, C.; Delval, A.; Tiffreau, V.; Defebvre, L.; Dujardin, K.; Duhamel, A.; Petyt, G.; Hossein-
Foucher, C.; Blum, D.; Sablonniere, B.; Schraen, S.; Allorge, D.; Destee, A.; Bordet, R.; Devos, D. 
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled 
pilot study. J Neurol Neurosurg Psychiatry, 2013, 84 (5), 552-5.
41. Varanese, S.; Howard, J.; Di Rocco, A. NMDA antagonist memantine improves levodopa-
induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov Disord, 2010, 25 (4), 508-
10.
42. Vidal, E. I.; Fukushima, F. B.; Valle, A. P.; Villas Boas, P. J. Unexpected improvement in 
levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment 
of Parkinson's disease dementia. J Am Geriatr Soc, 2013, 61 (1), 170-2.
43. Bigal, M.; Rapoport, A.; Sheftell, F.; Tepper, D.; Tepper, S. Memantine in the preventive 
treatment of refractory migraine. Headache, 2008, 48 (9), 1337-42.
44. Spengos, K.; Theleritis, C.; Paparrigopoulos, T. Memantine and NMDA antagonism for chronic
migraine: a potentially novel therapeutic approach? Headache, 2008, 48 (2), 284-6.
45. Chen, S. R.; Samoriski, G.; Pan, H. L. Antinociceptive effects of chronic administration of 
uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. 
Neuropharmacology, 2009, 57 (2), 121-6.
46. Morel, V.; Etienne, M.; Wattiez, A. S.; Dupuis, A.; Privat, A. M.; Chalus, M.; Eschalier, A.; 
Daulhac, L.; Pickering, G. Memantine, a promising drug for the prevention of neuropathic pain in rat. 
European journal of pharmacology, 2013, 721 (1-3), 382-90.
47. Pickering, G.; Morel, V.; Joly, D.; Villatte, C.; Roux, D.; Dubray, C.; Pereira, B. Prevention of 
post-mastectomy neuropathic pain with memantine: study protocol for a randomized controlled 
trial. Trials, 2014, 15, 331.
48. Lipton, S. A. Paradigm shift in NMDA receptor antagonist drug development: molecular 
mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and 
other neurologic disorders. Journal of Alzheimer's disease : JAD, 2004, 6 (6 Suppl), S61-74.
49. Behan, W. M.; McDonald, M.; Darlington, L. G.; Stone, T. W. Oxidative stress as a mechanism 
for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. British 
journal of pharmacology, 1999, 128 (8), 1754-60.
50. Rodriguez-Martinez, E.; Camacho, A.; Maldonado, P. D.; Pedraza-Chaverri, J.; Santamaria, D.; 
Galvan-Arzate, S.; Santamaria, A. Effect of quinolinic acid on endogenous antioxidants in rat corpus 
striatum. Brain Res, 2000, 858 (2), 436-9.
51. Rios, C.; Santamaria, A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. 
Neurochem Res, 1991, 16 (10), 1139-43.
52. Connick, J. H.; Stone, T. W. Quinolinic acid effects on amino acid release from the rat cerebral
cortex in vitro and in vivo. British journal of pharmacology, 1988, 93 (4), 868-76.
53. Tavares, R. G.; Tasca, C. I.; Santos, C. E.; Alves, L. B.; Porciuncula, L. O.; Emanuelli, T.; Souza, D.
O. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into 
astrocytes. Neurochem Int, 2002, 40 (7), 621-7.
54. Perkins, M. N.; Stone, T. W. Actions of kynurenic acid and quinolinic acid in the rat 
hippocampus in vivo. Exp Neurol, 1985, 88 (3), 570-9.
55. Swartz, K. J.; During, M. J.; Freese, A.; Beal, M. F. Cerebral synthesis and release of kynurenic 
acid: an endogenous antagonist of excitatory amino acid receptors. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 1990, 10 (9), 2965-73.
56. Birch, P. J.; Grossman, C. J.; Hayes, A. G. Kynurenic acid antagonises responses to NMDA via 
an action at the strychnine-insensitive glycine receptor. European journal of pharmacology, 1988, 
154 (1), 85-7.
57. Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A glycine site associated with N-methyl-D-
aspartic acid receptors: characterization and identification of a new class of antagonists. J 
Neurochem, 1989, 52 (4), 1319-28.
58. Hilmas, C.; Pereira, E. F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E. X. The 
brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 
nicotinic receptor expression: physiopathological implications. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 2001, 21 (19), 7463-73.
59. Marchi, M.; Risso, F.; Viola, C.; Cavazzani, P.; Raiteri, M. Direct evidence that release-
stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain 
glutamatergic axon terminals. J Neurochem, 2002, 80 (6), 1071-8.
60. Carpenedo, R.; Pittaluga, A.; Cozzi, A.; Attucci, S.; Galli, A.; Raiteri, M.; Moroni, F. Presynaptic 
kynurenate-sensitive receptors inhibit glutamate release. The European journal of neuroscience, 
2001, 13 (11), 2141-7.
61. Prescott, C.; Weeks, A. M.; Staley, K. J.; Partin, K. M. Kynurenic acid has a dual action on 
AMPA receptor responses. Neurosci Lett, 2006, 402 (1-2), 108-12.
62. Rozsa, E.; Robotka, H.; Vecsei, L.; Toldi, J. The Janus-face kynurenic acid. J Neural Transm, 
2008, 115 (8), 1087-91.
63. Csapo, E.; Majlath, Z.; Juhasz, A.; Roosz, B.; Hetenyi, A.; Toth, G. K.; Tajti, J.; Vecsei, L.; 
Dekany, I. Determination of binding capacity and adsorption enthalpy between Human Glutamate 
Receptor (GluR1) peptide fragments and kynurenic acid by surface plasmon resonance experiments. 
Colloids Surf B Biointerfaces, 2014, 123, 924-9.
64. Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H.; Ling, L. Kynurenic acid 
as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem, 2006, 281 (31), 22021-8.
65. Tajti, J.; Majlath, Z.; Szok, D.; Csati, A.; Toldi, J.; Fulop, F.; Vecsei, L. Novel kynurenic Acid 
Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and 
Pharmaceutical Design. Curr Pharm Des, 2015.
66. Mo, X.; Pi, L.; Yang, J.; Xiang, Z.; Tang, A. Serum indoleamine 2,3-dioxygenase and kynurenine 
aminotransferase enzyme activity in patients with ischemic stroke. J Clin Neurosci, 2014, 21 (3), 482-
6.
67. Widner, B.; Leblhuber, F.; Walli, J.; Tilz, G. P.; Demel, U.; Fuchs, D. Tryptophan degradation 
and immune activation in Alzheimer's disease. J Neural Transm, 2000, 107 (3), 343-53.
68. Guillemin, G. J.; Brew, B. J.; Noonan, C. E.; Takikawa, O.; Cullen, K. M. Indoleamine 2,3 
dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol 
Appl Neurobiol, 2005, 31 (4), 395-404.
69. Guillemin, G. J.; Smythe, G. A.; Veas, L. A.; Takikawa, O.; Brew, B. J. A beta 1-42 induces 
production of quinolinic acid by human macrophages and microglia. Neuroreport, 2003, 14 (18), 
2311-5.
70. Rahman, A.; Ting, K.; Cullen, K. M.; Braidy, N.; Brew, B. J.; Guillemin, G. J. The excitotoxin 
quinolinic acid induces tau phosphorylation in human neurons. PLoS One, 2009, 4 (7), e6344.
71. Szalardy, L.; Klivenyi, P.; Zadori, D.; Fulop, F.; Toldi, J.; Vecsei, L. Mitochondrial disturbances, 
tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr Med Chem, 2012,
19 (13), 1899-920.
72. Stone, T. W.; Forrest, C. M.; Stoy, N.; Darlington, L. G. Involvement of kynurenines in 
Huntington's disease and stroke-induced brain damage. J Neural Transm, 2012, 119 (2), 261-74.
73. Klein, C.; Patte-Mensah, C.; Taleb, O.; Bourguignon, J. J.; Schmitt, M.; Bihel, F.; Maitre, M.; 
Mensah-Nyagan, A. G. The neuroprotector kynurenic acid increases neuronal cell survival through 
neprilysin induction. Neuropharmacology, 2013, 70, 254-60.
74. Graham, W. C.; Robertson, R. G.; Sambrook, M. A.; Crossman, A. R. Injection of excitatory 
amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life sciences, 
1990, 47 (18), PL91-7.
75. Carrillo-Mora, P.; Mendez-Cuesta, L. A.; Perez-De La Cruz, V.; Fortoul-van Der Goes, T. I.; 
Santamaria, A. Protective effect of systemic L-kynurenine and probenecid administration on 
behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat 
hippocampus. Behavioural brain research, 2010, 210 (2), 240-50.
76. Silva-Adaya, D.; Perez-De La Cruz, V.; Villeda-Hernandez, J.; Carrillo-Mora, P.; Gonzalez-
Herrera, I. G.; Garcia, E.; Colin-Barenque, L.; Pedraza-Chaverri, J.; Santamaria, A. Protective effect of 
L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of 
modulating kynurenate as a protective strategy. Neurotoxicology and teratology, 2011, 33 (2), 303-
12.
77. Pineda-Farias, J. B.; Perez-Severiano, F.; Gonzalez-Esquivel, D. F.; Barragan-Iglesias, P.; Bravo-
Hernandez, M.; Cervantes-Duran, C.; Aguilera, P.; Rios, C.; Granados-Soto, V. The L-kynurenine-
probenecid combination reduces neuropathic pain in rats. Eur J Pain, 2013, 17 (9), 1365-73.
78. Zwilling, D.; Huang, S. Y.; Sathyasaikumar, K. V.; Notarangelo, F. M.; Guidetti, P.; Wu, H. Q.; 
Lee, J.; Truong, J.; Andrews-Zwilling, Y.; Hsieh, E. W.; Louie, J. Y.; Wu, T.; Scearce-Levie, K.; Patrick, C.; 
Adame, A.; Giorgini, F.; Moussaoui, S.; Laue, G.; Rassoulpour, A.; Flik, G.; Huang, Y.; Muchowski, J. M.;
Masliah, E.; Schwarcz, R.; Muchowski, P. J. Kynurenine 3-monooxygenase inhibition in blood 
ameliorates neurodegeneration. Cell, 2011, 145 (6), 863-74.
79. Gregoire, L.; Rassoulpour, A.; Guidetti, P.; Samadi, P.; Bedard, P. J.; Izzo, E.; Schwarcz, R.; Di 
Paolo, T. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced 
dyskinesias in parkinsonian monkeys. Behavioural brain research, 2008, 186 (2), 161-7.
80. Ouattara, B.; Belkhir, S.; Morissette, M.; Dridi, M.; Samadi, P.; Gregoire, L.; Meltzer, L. T.; Di 
Paolo, T. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 
61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci, 2009, 38 (2), 128-42.
81. Acuna-Castroviejo, D.; Tapias, V.; Lopez, L. C.; Doerrier, C.; Camacho, E.; Carrion, M. D.; Mora,
F.; Espinosa, A.; Escames, G. Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Brain research bulletin, 2011, 85 (3-4), 133-
40.
82. Wu, H. Q.; Lee, S. C.; Schwarcz, R. Systemic administration of 4-chlorokynurenine prevents 
quinolinate neurotoxicity in the rat hippocampus. European journal of pharmacology, 2000, 390 (3), 
267-74.
83. Zadori, D.; Nyiri, G.; Szonyi, A.; Szatmari, I.; Fulop, F.; Toldi, J.; Freund, T. F.; Vecsei, L.; 
Klivenyi, P. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model 
of Huntington's disease. J Neural Transm, 2011, 118 (6), 865-75.
84. Gellert, L.; Fuzik, J.; Goblos, A.; Sarkozi, K.; Marosi, M.; Kis, Z.; Farkas, T.; Szatmari, I.; Fulop, 
F.; Vecsei, L.; Toldi, J. Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion 
model of ischemia. European journal of pharmacology, 2011, 667 (1-3), 182-7.
85. Marosi, M.; Nagy, D.; Farkas, T.; Kis, Z.; Rozsa, E.; Robotka, H.; Fulop, F.; Vecsei, L.; Toldi, J. A 
novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological 
study. J Neural Transm, 2010, 117 (2), 183-8.
86. Knyihar-Csillik, E.; Mihaly, A.; Krisztin-Peva, B.; Robotka, H.; Szatmari, I.; Fulop, F.; Toldi, J.; 
Csillik, B.; Vecsei, L. The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-
fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-
72 and kynurenic acid. Neurosci Res, 2008, 61 (4), 429-32.
87. Vamos, E.; Pardutz, A.; Varga, H.; Bohar, Z.; Tajti, J.; Fulop, F.; Toldi, J.; Vecsei, L. l-kynurenine 
combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-
induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology, 2009, 57 (4), 425-9.
88. Nagy, K.; Plangar, I.; Tuka, B.; Gellert, L.; Varga, D.; Demeter, I.; Farkas, T.; Kis, Z.; Marosi, M.; 
Zadori, D.; Klivenyi, P.; Fulop, F.; Szatmari, I.; Vecsei, L.; Toldi, J. Synthesis and biological effects of 
some kynurenic acid analogs. Bioorg Med Chem, 2011, 19 (24), 7590-6.
89. Justinova, Z.; Mascia, P.; Wu, H. Q.; Secci, M. E.; Redhi, G. H.; Panlilio, L. V.; Scherma, M.; 
Barnes, C.; Parashos, A.; Zara, T.; Fratta, W.; Solinas, M.; Pistis, M.; Bergman, J.; Kangas, B. D.; Ferre, 
S.; Tanda, G.; Schwarcz, R.; Goldberg, S. R. Reducing cannabinoid abuse and preventing relapse by 
enhancing endogenous brain levels of kynurenic acid. Nat Neurosci, 2013, 16 (11), 1652-61.
90. Gellert, L.; Varga, D.; Ruszka, M.; Toldi, J.; Farkas, T.; Szatmari, I.; Fulop, F.; Vecsei, L.; Kis, Z. 
Behavioural studies with a newly developed neuroprotective KYNA-amide. J Neural Transm, 2012, 
119 (2), 165-72.
91. Demeter, I.; Nagy, K.; Farkas, T.; Kis, Z.; Kocsis, K.; Knapp, L.; Gellert, L.; Fulop, F.; Vecsei, L.; 
Toldi, J. Paradox effects of kynurenines on LTP induction in the Wistar rat. An in vivo study. Neurosci 
Lett, 2013, 553, 138-41.
92. Vecsei, L.; Szalardy, L.; Fulop, F.; Toldi, J. Kynurenines in the CNS: recent advances and new 
questions. Nature reviews. Drug discovery, 2013, 12 (1), 64-82.
93. Li, F.; Tsien, J. Z. Memory and the NMDA receptors. The New England journal of medicine, 
2009, 361 (3), 302-3.
94. Winn, P.; Stone, T. W.; Latimer, M.; Hastings, M. H.; Clark, A. J. A comparison of excitotoxic 
lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or 
quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the
rat. British journal of pharmacology, 1991, 102 (4), 904-8.
95. Szalardy, L.; Zadori, D.; Toldi, J.; Fulop, F.; Klivenyi, P.; Vecsei, L. Manipulating kynurenic acid 
levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Current topics 
in medicinal chemistry, 2012, 12 (16), 1797-806.
96. Wesnes, K. A.; Aarsland, D.; Ballard, C.; Londos, E. Memantine improves attention and 
episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. International 
journal of geriatric psychiatry, 2015, 30 (1), 46-54.
97. Anitha, M.; Nandhu, M. S.; Anju, T. R.; Jes, P.; Paulose, C. S. Targeting glutamate mediated 
excitotoxicity in Huntington's disease: neural progenitors and partial glutamate antagonist--
memantine. Medical hypotheses, 2011, 76 (1), 138-40.
98. Milnerwood, A. J.; Kaufman, A. M.; Sepers, M. D.; Gladding, C. M.; Zhang, L.; Wang, L.; Fan, J.;
Coquinco, A.; Qiao, J. Y.; Lee, H.; Wang, Y. T.; Cynader, M.; Raymond, L. A. Mitigation of augmented 
extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's 
disease mice. Neurobiology of disease, 2012, 48 (1), 40-51.
99. Sulkowski, G.; Dabrowska-Bouta, B.; Salinska, E.; Struzynska, L. Modulation of glutamate 
transport and receptor binding by glutamate receptor antagonists in EAE rat brain. PloS one, 2014, 9 
(11), e113954.
100. Zaitsev, A. V.; Kim, K.; Vasilev, D. S.; Lukomskaya, N. Y.; Lavrentyeva, V. V.; Tumanova, N. L.; 
Zhuravin, I. A.; Magazanik, L. G. N-methyl-D-aspartate receptor channel blockers prevent 
pentylenetetrazole-induced convulsions and morphological changes in rat brain neurons. Journal of 
neuroscience research, 2015, 93 (3), 454-65.
101. Miranda, A. F.; Boegman, R. J.; Beninger, R. J.; Jhamandas, K. Protection against quinolinic 
acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. 
Neuroscience, 1997, 78 (4), 967-75.
102. Heyliger, S. O.; Goodman, C. B.; Ngong, J. M.; Soliman, K. F. The analgesic effects of 
tryptophan and its metabolites in the rat. Pharmacological research, 1998, 38 (4), 243-50.
103. Platten, M.; Ho, P. P.; Youssef, S.; Fontoura, P.; Garren, H.; Hur, E. M.; Gupta, R.; Lee, L. Y.; 
Kidd, B. A.; Robinson, W. H.; Sobel, R. A.; Selley, M. L.; Steinman, L. Treatment of autoimmune 
neuroinflammation with a synthetic tryptophan metabolite. Science, 2005, 310 (5749), 850-5.
104. Kloc, R.; Luchowska, E.; Wielosz, M.; Owe-Larsson, B.; Urbanska, E. M. Memantine increases 
brain production of kynurenic acid via protein kinase A-dependent mechanism. Neurosci Lett, 2008, 
435 (2), 169-73.
105. D'Andrea, M. R.; Nagele, R. G. Targeting the alpha 7 nicotinic acetylcholine receptor to 
reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des, 2006, 12 
(6), 677-84.
106. Turski, W. A.; Malaczewska, J.; Marciniak, S.; Bednarski, J.; Turski, M. P.; Jablonski, M.; 
Siwicki, A. K. On the toxicity of kynurenic acid in vivo and in vitro. Pharmacol Rep, 2014, 66 (6), 1127-
33.
Figur e  lege n d s :
Figur e  1.  The  chemical  struc tu r e  of  memant ine
Figur e  2.  The  affinity  of  the  memant ine  to  the  NMDA  recep to r
①: Resting conditions: NMDA receptors with the physiological Mg2+ block
②: Increased background: Left side: low to moderate affinity antagonist memantine binding to the 
NMDA receptor, Right side: without memantine the NMDA receptor is getting activated after the 
binding of glycin and glutamate
③: Synaptic activity: Left side:after depolarization, without the memantine , the NMDA receptor is 
activated by the glycin and glutamate, Right side: after the depolarization the NMDA receptor 
becomes activated by the binding of glycin and glutamate, the Mg2+ block ceases
        :memantine,       :  glutamate, ○:Mg2+, ●: glycin
Figure 3. The kynurenine pathway
1: tryptophan dioxygenase (TDO) and indoleamine-2,3-dioxygenase (IDO), 2: formamidase, 
3: kynurenine aminotransferase, 4: kynurenine-3-monooxygenase (KMO), 5: kynureninase, 
6:kynurenine aminotransferase, 7:kynureninase,  8: 3-hydroxyanthranilic acid dioxygenase, 
9: quinolinic acid phosphoribosyltransferase
Figure 4.
A: Normal conditions: After Ca2+ influx from the α7-nicotinic acetylcholine receptors, the glutamate is
releasing and binding to its receptors (extrasynaptic NMDAR, synaptic NMDAR, AMPAR) on the 
postsynaptic surface of the neurons.
B: With kynurenic acid: After releasing into the perisynaptic area, KYNA exerts inhibition on 
extrasynaptic NMDARs and α7-nicotinic acetylcholine receptors ,while sparing synaptic NMDAR and 
AMPA receptor- mediated currents. In some articles it is mentioned that it has a Janus-faced impact on 
the AMPA receptors- e.g. it exerts a concentration-dependent dual effect.
         : glutamate, ●: glycin,           : Kynurenic acid 
